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ABSTRACT
Objective: The present work focuses on sterility studies of prepared aciclovir ocusert which is so essential for ophthalmic preparations. According 
to Indian Pharmacopoeia, the sterility test was performed. Ocuserts are sterile preparations which are placed into cul-de-sac or conjunctival sac. 
Ophthalmic inserts offer many advantages over conventional dosage forms such as increased ocular residence time, possibility of releasing drugs 
at a slow and constant rate and accurate dosing. Ocuserts are formulated for treating external ocular diseases such as conjuctivitis, corneal ulcer, 
and keratoconjuctivitis. Ophthalmic preparations contaminated with microorganisms cause corneal damage and finally blindness, especially if the 
microorganism is Pseudomonas aeruginosa. Ophthalmic preparations should be manufactured in aseptic condition and to be sterilized before packing.
Methods: According to Indian Pharmacopoeia, the official sterility test for ocusert was performed for detecting the presence of microbes. The selected 
F2 formulation which shows controlled drug release after 24 hrs was selected for the sterility test. The F2 formulation was subjected to ultraviolet 
radiation for sterilization. The sterilized ocusert and unsterilized ocusert were placed in fluid thioglycollate medium and incubated for 7 days at 
20-25oC.
Results: After 7 days of incubation, the sterilized ocusert shows no microbial growth and unsterilized ocusert shows microbial growth. The prepared 
aciclovir ocuserts were found to be sterile after the completion of official sterility test.
Conclusion: The sterility studies conclude after 7 days of incubation period; there was no appearance of turbidity which indicates the prepared 
formulation F2 was found to be sterile.
Keywords: Ocusert, Sterility test, Indian Pharmacopoeia, Ophthalmic drug delivery.
INTRODUCTION
Ophthalmic is defined as dosage forms intended to be administered 
on to the external surface, inside and adjacent to the eye. Based on the 
site of administration, the ophthalmic is named as topical preparation, 
(external surface of the eye) intraocular preparation (inside the eye) 
and periocular preparations (adjacent to the eye).The capacity of eye 
to accommodate the dosage form is less, so they are administered in 
small amounts. Only small quantity of drug gets absorbed due to less 
contact time and quick drainage in the eye. The field of ocular drug 
delivery is one of the most interesting and challenging endeavors 
facing the pharmaceutical scientist. The usefulness of this route of drug 
administration can be easily appreciated because the drug enters the 
systemic circulation circumventing the hepatic first pass effect [1]. 
(1) Improving ocular contact time, (2) enhancing corneal permeability, 
and (3) enhancing site specificity [1].
Ophthalmic preparations are the sterile product, meant for the 
installation into the eye in the space between the eyelid and the eyeball. 
These products must be isotonic with lachrymal secretion to avoid 
discomforts and irritations. The pH should be controlled up to 8.0 to 
avoid irritations [2-4]. Vehicles in the preparation must have good 
wetting ability to penetrate cornea and other tissues. The anatomy of 
eye is shown in Fig. 1.
Ocusert system is a novel ocular drug delivery system based on porous 
membrane. The release of drug from diffusion inserts/ocusert is based 
on a diffusion release mechanism. It consists of a central reservoir of 
drug enclosed in specially designed micro porous membrane allowing 
the drug to diffuse from the reservoir at a precisely determined 
rate. Aciclovir is the prototype antiviral agent used to treat various 
types of herpes infections. Since aciclovir was the first antiviral to be 
considered the gold standard for the treatment of herpes infections; 
all other antiherpes virus medications are compared to it. The drug 
is approved for the treatment of herpes simplex keratitis, herpes 
simplex encephalitis, herpes genitalis, herpes labialis, herpes zoster, 
varicella (chickenpox), varicella-zoster virus, and viral conjunctivitis. 
It is approved for the prophylaxis of herpes genitalis. The aciclovir 
structural formula is shown in Fig. 2.
The desired criteria for a controlled release ocular inserts are:
•	 Comfort,	 lack	of	 explosion,	 easy	of	handling	and	 insertion,	non-
interference with vision and oxygen permeability, reproducibility 
of release kinetics, sterility, stability and easy of manufacture.
Herpes virus
Herpes simplex virus is a DNA virus that commonly affects humans. 
Infection occurs by direct contact of skin or mucous membrane with 
virus laden lesions or secretions. Herpes virus is shown in Fig. 3.
A polymer, natural or synthetic is a substance that is combined with a 
drug or other active agent to release drug in a predesigned manner [5,6]. 
Ocular inserts are least affected by nasolacrimal drainage, and tear flow 
thus provides reliable drug release and longer residence in cul-de-sac [7].
METHODS
All the ingredients used were of analytical grade. Aciclovir was received 
as a gift sample from Kaushik Therapeutics Pvt. Ltd., Chennai. Soya 
bean casein medium, agar, sodium hydroxide, potassium dihydrogen 
phosphate, ammonium chloride and calcium chloride was purchased 
from Qualigens Fine Chemicals, Mumbai.
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Sterility test [8-10]
Sterility tests were based on the principle that if bacteria or fungi are 
placed in a medium which provided nutritive material, moisture, and 
the desired pH and kept at a favorable temperature, the organism will 
grow and their presence can be indicated by the growth in originally 
medium. The tests for sterility were done by detecting the presence of 
viable forms of bacteria, fungi and yeast in or on preparations. The tests 
were carried out under strict aseptic techniques to avoid accidental 
contamination of the preparation.
Sterility test for ocusert [11-13]
The ocuserts were subjected to sterility test. The test for sterility 
was intended for detecting the presence of viable forms of bacteria, 
fungi, and yeast in preparations. The tests were carried out under 
aseptic conditions to avoid contamination of the product during the 
test.
Culture media
For anaerobic bacteria and fungi.
Medium: Soya bean casein medium.
This medium can be used for the detection of anaerobic bacteria and 
fungi.
Preparation of soya bean casein medium
The ingredients pancreatic digest of casein 17 g, papic digest of 
soya bean 3 g, sodium chloride 2.5 g, dibasic potassium phosphate 
2.5 g, and dextrose 2.5 g were dissolved completely in 1000 ml of 
distilled water, and the medium was boiled for 10 minutes. The pH 
was adjusted to 7.3±0.2. Media was distributed into 9 cm diameter 
Petri dishes.
Sterilization of medium [14,15]
Anaerobic culture medium was sterilized by autoclaving at a pressure 
of 15l lb and a temperature of 121°C for 15 minutes. Autoclaved 
medium was kept in room temperature before inoculation of the 
sample.
Incubation
The sterilized ocuserts and unsterilized ocuserts were placed into 
fluid thioglycolate medium and incubated at 20-25°C for not <7 days. 
At specific intervals during the incubation period, the media were 
examined visually for microbial growth.
Control test [16,17]
To support the above-performed test, a positive control and negative 
control test were also carried out for quality control maintenance. 
Negative control test was carried out to confirm that the media and the 




After in vitro drug release studies, best formulation F2 was selected. The 
selected formulation was sterilized by ultraviolet-radiation technique. 
Then, sterility testing was performed and the results were reported in 
Table 1.
Growth of microorganisms was noticed during the 7 days of incubation 
period in unsterilized ocusert, and there was no growth in sterilized 
ocusert. Thus, sterilized ocusert passes the test for sterility for 
anaerobic microorganism, and there was no growth which indicates 
ocusert can be used for ophthalmic purpose.
CONCLUSION
The sterility testing was very important evaluation for the 
ophthalmic preparations to check the presence of microorganisms. 
Because microorganisms presence in ophthalmic formulations 
may damage the eye and causes complete loss of vision. According 
to Indian Pharmacopoeia the sterility testing for the selected 
formulation F2 was carried out. The prepared ophthalmic ocuserts 
passes the sterility test as there was no turbidity appearance after 
the completion of the sterility test. As there was no appearance of 
growth of microorganisms, the ophthalmic ocuserts can be used for 
ophthalmic purpose.
Fig. 1: Anatomy of eye
Fig. 2: Structural formula of aciclovir
Table 1: Sterility testing results of selected formulation (F2)
Type of ocusert Growth of microorganism
Negative control Presence
Nonsterilized ocusert Presence
Sterilized ocusert AbsentFig. 3: Herpes virus
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